Hypereosinophilic syndrome
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Hypereosinophilic syndrome Classification and external resources | |
| ICD-10 | D72.1 (ILDS D72.12) |
|---|---|
| ICD-9 | 288.3 |
| ICD-O: | 9964/3 |
| OMIM | 607685 |
| eMedicine | med/1076 derm/920 |
| MeSH | D017681 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Phone:617-525-7431
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
The hypereosinophilic syndrome is a disease process characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause after a careful workup, with evidence of involvement of either the heart, nervous system, or bone marrow.
Classification
There are two forms of the hypereosinophilic syndrome: Endomyocardial fibrosis and Loeffler's endocarditis.
- Endomyocardial fibrosis (also known as Davies disease) is seen in Africa and South America.
- Loeffler's endocarditis does not have any geographic predisposition.
Presentation
In both forms of the hypereosinophilic syndrome, the eosinophilia causes infiltration of the myocardium of the heart, which leads to fibrotic thickening of portions of the heart. The portions of the heart most affected by this disease are the apex of the left and right ventricles, but fibrotic infiltrations may also involve the mitral or tricuspid valves. Because of the infiltrative nature of the disease process, the cavity of the ventricles of the heart diminish in size, causing an obliterative cardiomyopathy and restriction to the inflow of blood in to the chambers of the heart. Ventricular mural thrombi may develop.
Relationship to chronic eosinophilic leukemia
Chronic eosinophilic leukemia (CEL) is a myeloproliferative disease which shares many common characteristics with hypereosinophilic syndrome. Many cases of CEL have a characteristic gene rearrangement , FIP1L1/PDGFRA, caused by a sub-microscopic deletion of ~800 thousand base pairs of DNA on chromosome 4.[1] The FIP1L1/PDGFRA fusion gene causes constitutive activation of the platelet derived growth factor receptor - alpha (PDGFRA). FIP1L1/PDGFRA-positive patients respond well to treatment with tyrosine kinase inhibitor drugs, such as imatinib mesylate (Gleevec® or Glivec®).
Pathological Findings
Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology
 Endomyocardial Fibrosis With Ventricular Thrombosis: Gross fixed tissue good color view from right atrium into right ventricle showing top of thrombus in right ventricle strange case of 43yo F with thrombi filling both ventricles cause completely unknown |
 Endomyocardial Fibrosis With Ventricular Thrombosis: Gross fixed tissue good color horizontal section of ventricles endocardial fibrosis thrombus and focal myocardial fibrosis are evident strange case with no evident cause |
 Endomyocardial Fibrosis With Ventricular Thrombosis: Gross fixed tissue color not to good horizontal section of ventricles showing thrombus filling both which is quite old and in left ventricle endocardial fibrosis and focal myocardial fibrosis cause unknown heart wt 550 gm |
 Endomyocardial Fibrosis With Ventricular Thrombosis: Gross fixed tissue not to bad color four horizontal sections of ventricles showing lumens filled with thrombus mostly old and on left endocardial fibrosis 43 year old female cause completely unknown ventricles had slowing filled with thrombus |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME Blood smear from a 50-year-old male with a 3-year history of hypereosinophilic syndrome with progressive bone marrow failure and multiple organ involvement. The three eosinophils show marked hypogranulation. (Wright-Giemsa stain) |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME Bone marrow smear from the patient in A showing a marked increase in eosinophils at all stages of maturation. Some of the granules in immature eosinophils have a basophilic color and two of the eosinophil myelocytes have a diminished number of granules. (Wright-Giemsa stain) |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME Bone marrow biopsy showing marked hypercellularity due primarily to an increase in eosinophils and precursors. Megakaryocytes are markedly reduced. Increased reticulin fibers are present. Despite intensive chemotherapy there was a progressive increase in marrow fibrosis and number of blasts. The patient died of central nervous system failure 17 months after this specimen was obtained. (Hematoxylin and eosin stain) |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME WITH MYELOFIBROSIS Bone marrow biopsy. The marrow is markedly fibrotic. (Hematoxylin and eosin stain) |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME WITH MYELOFIBROSIS High magnification of the specimen on the left. Blasts and immature cells are scattered throughout the fibrotic tissue. (Hematoxylin and eosin stain) |
 BONE MARROW: HYPEREOSINOPHILIC SYNDROME: ULTRASTRUCTURE Electron micrograph of an abnormal eosinophil from the specimen in figure 274B. There is a decreased number of granules. The majority of the granules present are homogeneous in contrast to normal eosinophil granules which have a dense core surrounded by a less dense capsule. (Uranyl acetate-lead citrate stains, X20,000) |
 BONE MARROW: MAST CELL LEUKEMIA AND EOSINOPHILIA A blood smear from a young woman with mast cell leukemia and marked eosinophilia. There are five eosinophils, one neutrophil, and a large atypical-appearing mast cell with relatively sparse small granules and a slightly lobulated nucleus. This patient had eosinophilia as a presenting feature and was initially thought to have a hypereosinophilic syndrome. Eosinophilia is observed in approximately one third of patients with systemic mast cell disease. (Wright-Giemsa stain) |
References
External links
WikiDoc Research Resources for Hypereosinophilic syndrome | |
|---|---|
| Articles on Hypereosinophilic syndrome | Most recent articles on Hypereosinophilic syndrome • Most cited articles on Hypereosinophilic syndrome • Review articles on Hypereosinophilic syndrome • Articles on Hypereosinophilic syndrome in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Hypereosinophilic syndrome | Powerpoint slides on Hypereosinophilic syndrome • Images of Hypereosinophilic syndrome • Photos of Hypereosinophilic syndrome • Podcasts & MP3s on Hypereosinophilic syndrome • Videos on Hypereosinophilic syndrome |
| Evidence Based Medicine Regarding Hypereosinophilic syndrome | Cochrane Collaboration on Hypereosinophilic syndrome • Bandolier on Hypereosinophilic syndrome • TRIP on Hypereosinophilic syndrome |
| Cost Effectiveness of Hypereosinophilic syndrome | Cost Effectiveness of Hypereosinophilic syndrome |
| Clinical Trials Involving Hypereosinophilic syndrome | Ongoing Trials on Hypereosinophilic syndrome at Clinical Trials.gov • Trial results on Hypereosinophilic syndrome • Clinical Trials on Hypereosinophilic syndrome at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Hypereosinophilic syndrome | US National Guidelines Clearinghouse on Hypereosinophilic syndrome • NICE Guidance on Hypereosinophilic syndrome • NHS PRODIGY Guidance • FDA on Hypereosinophilic syndrome • CDC on Hypereosinophilic syndrome |
| Textbook Information on Hypereosinophilic syndrome | Books and Textbook Information on Hypereosinophilic syndrome |
| Pharmacology Resources on Hypereosinophilic syndrome | Dosing of Hypereosinophilic syndrome • Drug interactions with Hypereosinophilic syndrome • Side effects of Hypereosinophilic syndrome • Allergic reactions to Hypereosinophilic syndrome • Overdose information on Hypereosinophilic syndrome • Carcinogenicity information on Hypereosinophilic syndrome • Hypereosinophilic syndrome in pregnancy • Pharmacokinetics of Hypereosinophilic syndrome • |
| Genetics, Pharmacogenomics, and Proteinomics of Hypereosinophilic syndrome | Genetics of Hypereosinophilic syndrome • Pharmacogenomics of Hypereosinophilic syndrome • Proteomics of Hypereosinophilic syndrome |
| Newstories on Hypereosinophilic syndrome | Hypereosinophilic syndrome in the news • Be alerted to news on Hypereosinophilic syndrome • News trends on Hypereosinophilic syndrome |
| Commentary on Hypereosinophilic syndrome | Blogs on Hypereosinophilic syndrome |
| Patient Resources on Hypereosinophilic syndrome | Patient resources on Hypereosinophilic syndrome • Discussion groups on Hypereosinophilic syndrome • Patient Handouts on Hypereosinophilic syndrome • Directions to Hospitals Treating Hypereosinophilic syndrome • Risk calculators and risk factors for Hypereosinophilic syndrome |
| Healthcare Provider Resources on Hypereosinophilic syndrome | Symptoms of Hypereosinophilic syndrome • Causes & Risk Factors for Hypereosinophilic syndrome • Diagnostic studies for Hypereosinophilic syndrome • Treatment of Hypereosinophilic syndrome |
| Continuing Medical Education (CME) Programs on Hypereosinophilic syndrome | CME Programs on Hypereosinophilic syndrome |
| International Resources on Hypereosinophilic syndrome | Hypereosinophilic syndrome en Espanol • Hypereosinophilic syndrome en Francais |
| Business Resources on Hypereosinophilic syndrome | Hypereosinophilic syndrome in the Marketplace • Patents on Hypereosinophilic syndrome |
| Informatics Resources on Hypereosinophilic syndrome | List of terms related to Hypereosinophilic syndrome |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
